Incyte shares have climbed 8.6% to $114.25 over the past six months, closely tracking the S&P 500's 8.2% gain. The biopharmaceutical company grew revenue at a 15% compound annual rate over the last five years, outpacing the average healthcare firm, and its trailing 12-month free cash flow margin reached 27.7% after expanding by 8 percentage points during that period. However, return on invested capital has declined significantly in recent years, raising questions about the payoff from new investments. The stock trades at 20.3 times forward earnings.
Incyte CorporationArticle reports stock price performance and financial metrics (revenue growth, FCF margin, ROIC decline, valuation) without a specific catalyst.